| Year |
Citation |
Score |
| 2023 |
Babigumira JB, Karichu JK, Clark S, Cheng MM, Garrison LP, Maniecki MB, Hamid SS. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison. Bmj Open. 13: e066770. PMID 37142306 DOI: 10.1136/bmjopen-2022-066770 |
0.46 |
|
| 2021 |
Saldarriaga EM, Cárcamo CP, Babigumira JB, García PJ. The Annual costs of treating genital warts in the Public Healthcare Sector in Peru. Bmc Health Services Research. 21: 1092. PMID 34649539 DOI: 10.1186/s12913-021-07120-w |
0.347 |
|
| 2020 |
Graham SM, Agutu C, van der Elst E, Hassan AS, Gichuru E, Mugo PM, Farquhar C, Babigumira JB, Goodreau SM, Hamilton DT, Ndung'u T, Sirengo M, Chege W, Sanders EJ. A Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent HIV Infection in Young Adults and Reduce HIV Transmission in Kenya: Protocol for a Randomized Controlled Trial. Jmir Research Protocols. 9: e16198. PMID 32763882 DOI: 10.2196/16198 |
0.308 |
|
| 2020 |
Duarte HA, Babigumira JB, Enns EA, Stauffer DC, Shafer RW, Beck IA, Garrison LP, Chung MH, Frenkel LM, Bendavid E. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. Eclinicalmedicine. 22: 100355. PMID 32490370 DOI: 10.1016/J.Eclinm.2020.100355 |
0.564 |
|
| 2019 |
Soi C, Babigumira JB, Chilundo B, Muchanga V, Matsinhe L, Gimbel S, Augusto O, Sherr K. Implementation strategy and cost of Mozambique's HPV vaccine demonstration project. Bmc Public Health. 19: 1406. PMID 31664976 DOI: 10.1186/S12889-019-7793-Y |
0.389 |
|
| 2019 |
Schwartz NRM, Flanagan MR, Babigumira JB, Steuten LM, Roth JA. Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer. Journal of Managed Care & Specialty Pharmacy. 25: 1133-1139. PMID 31556818 DOI: 10.18553/Jmcp.2019.25.10.1133 |
0.349 |
|
| 2019 |
Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Stergachis A, Garrison LP, Babigumira JB. Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. Plos One. 14: e0217331. PMID 31170193 DOI: 10.1371/Journal.Pone.0217331 |
0.581 |
|
| 2019 |
Garrison LP, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 408-415. PMID 30975391 DOI: 10.1016/J.Jval.2018.11.014 |
0.545 |
|
| 2019 |
Schwartz NR, Flanagan MR, Babigumira JB, Steuten LMG, Roth JA. Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective? Journal of Clinical Oncology. 37: 6625-6625. DOI: 10.1200/Jco.2019.37.15_Suppl.6625 |
0.473 |
|
| 2018 |
Roth L, Bempong D, Babigumira JB, Banoo S, Cooke E, Jeffreys D, Kasonde L, Leufkens HGM, Lim JCW, Lumpkin M, Mahlangu G, Peeling RW, Rees H, Ndomondo-Sigonda M, Stergachis A, et al. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems. Globalization and Health. 14: 102. PMID 30382856 DOI: 10.1186/S12992-018-0421-2 |
0.33 |
|
| 2018 |
Wagner AD, Njuguna IN, Neary J, Omondi VO, Otieno VA, Babigumira J, Maleche-Obimbo E, Wamalwa DC, John-Stewart GC, Slyker JA. Financial Incentives to Increase Uptake of Pediatric HIV Testing (FIT): study protocol for a randomised controlled trial in Kenya. Bmj Open. 8: e024310. PMID 30287676 DOI: 10.1136/Bmjopen-2018-024310 |
0.339 |
|
| 2018 |
Lubinga S, Babigumira J, Graham S, Mukose A, Garrison L, Basu A. Heterogeneity in Preferences for Medical Male Circumcision Services: A Discrete Choice Experiment Among Uncircumcised Men In Fishing Communities in Uganda Value in Health. 21: S127. DOI: 10.1016/J.Jval.2018.04.961 |
0.449 |
|
| 2018 |
Schwartz N, Steuten L, Babigumira J, Roth J. Potential Cost-Effectiveness of Neratinib Following Trastuzumab Therapy for Treatment of Early-Stage Her2-Positive Breast Cancer Value in Health. 21. DOI: 10.1016/J.Jval.2018.04.179 |
0.364 |
|
| 2017 |
Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP, Babigumira JB. Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda. Papillomavirus Research (Amsterdam, Netherlands). 4: 17-21. PMID 29179864 DOI: 10.1016/J.Pvr.2017.06.004 |
0.483 |
|
| 2017 |
Nuwasiima A, Nuwamanya E, Navvuga P, Babigumira JU, Asiimwe FT, Lubinga SJ, Babigumira JB. Study protocol: incentives for increased access to comprehensive family planning for urban youth using a benefits card in Uganda. A quasi-experimental study. Reproductive Health. 14: 140. PMID 29078815 DOI: 10.1186/S12978-017-0400-8 |
0.306 |
|
| 2017 |
Babigumira JB, Sharara FI, Garrison LP. Projecting the potential impact of the Cap-Score™ on clinical pregnancy, live births, and medical costs in couples with unexplained infertility. Journal of Assisted Reproduction and Genetics. PMID 28942518 DOI: 10.1007/S10815-017-1021-4 |
0.575 |
|
| 2017 |
Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Effectiveness and Resource Allocation : C/E. 15: 13. PMID 28725164 DOI: 10.1186/S12962-017-0075-6 |
0.585 |
|
| 2017 |
Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP, Chung MH. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 136: 220-228. PMID 28099724 DOI: 10.1002/Ijgo.12025 |
0.579 |
|
| 2017 |
Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the Cost of Illness of Giant Cell Arteritis in the United States. Rheumatology and Therapy. PMID 28084585 DOI: 10.1007/s40744-017-0052-8 |
0.548 |
|
| 2016 |
Babigumira JB, Lubinga SJ, Castro E, Custer B. Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma. Blood Transfusion = Trasfusione Del Sangue. 1-9. PMID 27893348 DOI: 10.2450/2016.0130-16 |
0.355 |
|
| 2016 |
Watkins D, Lubinga SJ, Mayosi B, Babigumira JB. A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations. Plos Neglected Tropical Diseases. 10: e0004860. PMID 27512994 DOI: 10.1371/Journal.Pntd.0004860 |
0.371 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP, Stergachis A. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug Safety. PMID 27314405 DOI: 10.1007/S40264-016-0432-Y |
0.58 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiology and Drug Safety. PMID 27134056 DOI: 10.1002/Pds.4022 |
0.49 |
|
| 2016 |
Babigumira JB, Jenny AM, Bartlein R, Stergachis A, Garrison LP. Health technology assessment in low- and middle-income countries: A landscape assessment Journal of Pharmaceutical Health Services Research. DOI: 10.1111/Jphs.12120 |
0.506 |
|
| 2016 |
Babigumira J, Sharara F, Garrison L. Potential impact of the Cap-Score test™ on clinical pregnancy and medical costs in couples with unexplained infertility Fertility and Sterility. 106: e299. DOI: 10.1016/J.Fertnstert.2016.07.848 |
0.553 |
|
| 2015 |
Lubinga SJ, Atukunda EC, Wasswa-Ssalongo G, Babigumira JB. Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. Plos One. 10: e0142550. PMID 26560140 DOI: 10.1016/J.Jval.2014.03.937 |
0.404 |
|
| 2015 |
Garrison LP, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: 541-6. PMID 26091608 DOI: 10.1016/J.Jval.2015.01.012 |
0.524 |
|
| 2015 |
Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. Applied Health Economics and Health Policy. 13: 493-506. PMID 25958192 DOI: 10.1016/J.Jval.2015.03.710 |
0.319 |
|
| 2015 |
Verguet S, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, Levin CE, Nugent RA, Pecenka C, Shrime MG, Memirie ST, Watkins DA, Jamison DT. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. The Lancet. Global Health. 3: e288-96. PMID 25889470 DOI: 10.1016/S2214-109X(14)70346-8 |
0.308 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. THU0347 Estimating the Cost of Illness of Giant Cell Arteritis Annals of the Rheumatic Diseases. 74: 321.1-321. DOI: 10.1136/Annrheumdis-2015-Eular.5013 |
0.556 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating The Cost Of Illness Of Giant Cell Arteritis Value in Health. 18: A138. DOI: 10.1016/J.Jval.2015.03.805 |
0.568 |
|
| 2015 |
Watkins D, Lubinga S, Babigumira J. Strategies for prevention and control of rheumatic fever and rheumatic
heart disease in Sub-Saharan Africa: a preliminary cost-effectiveness
analysis Annals of Global Health. 81: 102. DOI: 10.1016/J.Aogh.2015.02.737 |
0.361 |
|
| 2014 |
Lubinga SJ, Jenny AM, Larsen-Cooper E, Crawford J, Matemba C, Stergachis A, Babigumira JB. Impact of pharmacy worker training and deployment on access to essential medicines and health outcomes in Malawi: protocol for a cluster quasi-experimental evaluation. Implementation Science : Is. 9: 156. PMID 25300317 DOI: 10.1186/S13012-014-0156-2 |
0.338 |
|
| 2014 |
Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Safety. 37: 127-34. PMID 24550105 DOI: 10.1007/S40264-014-0143-1 |
0.585 |
|
| 2014 |
Babigumira JB, Santos E, Antao VP, Wang B, Portera CC, Kamath T, Garrison LP. Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. Journal of Clinical Oncology. 32: 642-642. DOI: 10.1200/Jco.2014.32.15_Suppl.642 |
0.536 |
|
| 2014 |
Mann M, Babigumira J, Garrison L, Chung M. Assessing the Potential Cost-Effectiveness of Alternative Methods to Screen for Cervical Cancer Among HIV-Positive Women in Kenya Value in Health. 17: A82. DOI: 10.1016/J.Jval.2014.03.481 |
0.58 |
|
| 2013 |
Garrison LP, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer. 119: 3113-22. PMID 23775560 DOI: 10.1002/cncr.28196 |
0.538 |
|
| 2013 |
Mann M, Babigumira J. Economic evaluations of antiretroviral therapy monitoring using routine hiv viral load testing in low-income settings: A systematic review Value in Health. 16: A89. DOI: 10.1016/J.Jval.2013.03.413 |
0.301 |
|
| 2012 |
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Babigumira J, Garrison LP. Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 226. PMID 27983058 DOI: 10.1200/Jco.2012.30.15_Suppl.E14525 |
0.555 |
|
| 2012 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/Journal.Pone.0030735 |
0.618 |
|
| 2012 |
Garrison L, Babigumira J, Andrade S. PCN91 The Cost-Effectiveness of Trastuzumab Over the Product Life Cycle in Portugal: A Dynamic and Societal Perspective Value in Health. 15: A425. DOI: 10.1016/J.Jval.2012.08.2131 |
0.556 |
|
| 2011 |
Garrison LP, Lalla D, Brammer MG, Wang B, Babigumira J, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6133. PMID 28022481 DOI: 10.1200/jco.2011.29.15_suppl.6133 |
0.497 |
|
| 2011 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904 |
0.623 |
|
| 2011 |
Levin A, Burgess C, Garrison LP, Bauch C, Babigumira J, Simons E, Dabbagh A. Global eradication of measles: an epidemiologic and economic evaluation. The Journal of Infectious Diseases. 204: S98-106. PMID 21666220 DOI: 10.1093/Infdis/Jir096 |
0.583 |
|
| 2011 |
Babigumira JB, Levin A, Burgess C, Garrison LP, Bauch CT, Braka F, Mbabazi WB, Nabyonga JO, Simons E, Dabbagh A. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. The Journal of Infectious Diseases. 204: S116-23. PMID 21666152 DOI: 10.1093/Infdis/Jir132 |
0.618 |
|
| 2011 |
Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, Lamorde M, Kambugu A, Muwanga A, Garrison LP. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. Plos One. 6: e18193. PMID 21464895 DOI: 10.1371/Journal.Pone.0018193 |
0.614 |
|
| 2011 |
Babigumira J. PIH14 PROJECTING THE POTENTIAL COST-EFFECTIVENESS OF UNIVERSAL ACCESS TO MODERN CONTRACEPTIVES IN UGANDA Value in Health. 14: A107. DOI: 10.1016/J.Jval.2011.02.599 |
0.418 |
|
| 2009 |
Babigumira JB, Sethi AK, Smyth KA, Singer ME. Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics. 27: 963-73. PMID 19888795 DOI: 10.2165/11318230-000000000-00000 |
0.467 |
|
| 2009 |
Babigumira JB, Castelnuovo B, Lamorde M, Kambugu A, Stergachis A, Easterbrook P, Garrison LP. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. Bmc Health Services Research. 9: 192. PMID 19845963 DOI: 10.1186/1472-6963-9-192 |
0.585 |
|
| 2009 |
Garrison L, Bauch C, Babigumira J. VA3 GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020–2049 Value in Health. 12: A228. DOI: 10.1016/S1098-3015(10)74114-0 |
0.604 |
|
| 2009 |
Bresnahan B, Babigumira J, Veenstra D, Bauch C, Garrison L. PIN39 ASSESSING DISEASE BURDEN FOR MEASLES USING A CLINICAL AND HEALTH OUTCOMES APPROACH: A FOCUS ON LOWER-INCOME COUNTRIES Value in Health. 12: A117. DOI: 10.1016/S1098-3015(10)73647-0 |
0.506 |
|
| 2008 |
Babigumira J, Castelnuovo B, Lamorde M, Muwanga A, Kambugu A, Easterbrook P, Garrison L. PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA Value in Health. 11: A94-A95. DOI: 10.1016/S1098-3015(10)70307-7 |
0.536 |
|
| Show low-probability matches. |